| Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. | |
| | |
MedLine Citation:
|
PMID: 12040355 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Radiocontrast nephropathy (RCN) is a common source of acute renal failure in hospitalized patients and is associated with increased morbidity and mortality rates. Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow (RPF) in patients with normotensive and hypertensive conditions. To determine whether fenoldopam mesylate attenuates reductions in RPF after contrast infusion, we conducted a double-blind, randomized, placebo-controlled pilot trial of fenoldopam mesylate in patients who underwent contrast angiography. METHODS: Fifty-one patients with chronic renal insufficiency (creatinine level, 2.0-5.0 mg/dL) who were undergoing contrast angiography were screened, and 45 patients were randomized to receive normal saline solution (1/2 NS) or 1/2 NS plus fenoldopam mesylate at 0.1 microg/kg/min at lease 1 hour before infusion with contrast dye. Serum creatinine level was measured at baseline and at 24, 48, and 72 hours after angiography. The primary endpoint was change in RPF 1 hour after contrast infusion. The secondary endpoint was incidence of RCN, defined as a 0.5 mg/dL or a 25% rise in serum creatinine level at 48 hours. RESULTS: RPF at 1 hour after angiography was 15.8% above baseline in the fenoldopam mesylate group compared with 33.2% below baseline in the 1/2 NS group (P <.05). The incidence rate of RCN at 48 hours was 41.0% in the 1/2 NS group versus 21% in the fenoldopam mesylate group (P =.148). Among patients with diabetes, the incidence rate of RCN tended to be higher in the 1/2 NS group compared with the fenoldopam mesylate group (64% vs 33%; P =.14). The peak serum creatinine level at 72 hours after contrast infusion was significantly higher at in the 1/2 NS group (creatinine level, 3.6 +/- 1.0 mg/dL) compared with the fenoldopam mesylate group (creatinine level, 2.8 +/- 0.35 mg/dL; P <.05). RPF was significantly (P <.0001) reduced in patients with RCN compared with patients in whom RCN did not develop. CONCLUSION: The results of this pilot trial suggest that fenoldopam mesylate is a promising prophylactic agent for RCN and that larger multicenter trials should be conducted to prove its efficacy. |
| | |
Authors:
|
J A Tumlin; A Wang; P T Murray; V S Mathur |
Related Documents
:
|
20420795 - Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idio... 11385375 - Coronary artery bypass grafting in non-dialysis-dependent mild-to-moderate renal dysfun... 1699835 - Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites ... 17445645 - Long-term follow-up of hand-assisted laparoscopic radical nephrectomy for organ-confine... 2301715 - Clostridium difficile diarrhea and colonization after treatment with abdominal infectio... 17389745 - Pharmacokinetics of vancomycin following intracameral bolus injection in patients under... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: American heart journal Volume: 143 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2002 May |
Date Detail:
|
Created Date: 2002-05-31 Completed Date: 2002-06-10 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 894-903 Citation Subset: AIM; IM |
Affiliation:
|
Emory University School of Medicine, Atlanta, GA 30322, USA. JTUMLIN@emory.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Contrast Media / adverse effects* Double-Blind Method Female Fenoldopam / therapeutic use* Humans Kidney / blood supply, drug effects* Kidney Failure, Acute / chemically induced, prevention & control* Male Pilot Projects Prospective Studies Vasodilator Agents / therapeutic use* p-Aminohippuric Acid / adverse effects, diagnostic use* |
| Grant Support | |
ID/Acronym/Agency:
|
R01HL59978-01A1/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; 0/Vasodilator Agents; 61-78-9/p-Aminohippuric Acid; 67227-56-9/Fenoldopam |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Early reopening and recanalization after successful coil occlusion of the patent ductus arteriosus.
Next Document: Long-term outcome and the use of revascularization in patients with heart failure, suspected ischemi...